{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
glycerol phenylbutyrate
to a specific field?
Status:
Investigational
Source:
INN:mosedipimod [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
EC-18 (now known as mosedipimod), a synthetic copy of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) that was developed by Enzychem Lifescience for oral administration for the treatment of immune and inflammatory related diseases, including psoriasis, rheumatoid arthritis, asthma, atopic dermatitis, and sepsis. The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to EC-18 for the treatment of Acute Radiation Syndrome (ARS) and for the for the neutropenia treatment. Besides, the EC-18 is participating in phase II clinical trials to investigate the efficacy and safety of the agent for chemoradiation-induced oral mucositis and chemotherapy-induced neutropenia. This drug has a multimodal mechanism of action. It stimulates calcium influx into T lymphocytes and increases the production of various cytokines. In addition, EC-18 enhances the cytolytic activity of natural killer (NK) cells and suppresses the expression of the transmembrane protein tumor cell toll-like receptor 4 (TLR-4) on cancer cells, thus suppresses tumor cell proliferation.
Class (Stereo):
CHEMICAL (RACEMIC)
Glucalox an antacid that was used as a digestive agent. Information about the current use of this compound is not available.
Status:
Investigational
Source:
NCT00004450: Not Applicable Interventional Completed Adrenoleukodystrophy
(1998)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Glyceryl trierucate (trierucin) is a trierucic acid triglyceride that has been investigated for the treatment of adrenoleukodystrophy, a rare genetic disorder characterized by the breakdown or loss of myelin in the brain. To investigate treatment options for adrenoleukodystrophy, most studies have used “Lorenzo's oil" (LO), a 4:1 mixture of glyceryl trioleate and glyceryltrierucate. Lorenzo’s oil was found to reduce the levels of saturated very long chain fatty acids (ELOVL) in the plasma, adipose tissue and liver, but to a lesser extent in the brain. Inhibition of ELOVL 1 may be an underlying mechanism by which Lorenzo's oil exerts its action. Several clinical trials have been conducted to study the potential of glyceryl trierucate in treatment of adrenoleukodystrophy.
Class (Stereo):
CHEMICAL (MIXED)
Febuverine is a spasmolytic and local anesthetic.
Class (Stereo):
CHEMICAL (MIXED)
FENETRADIL is a coronary dilator.
Status:
Investigational
Source:
NCT00002677: Phase 1 Interventional Completed Prostate Cancer
(1995)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Tributyrin is a prodrug of natural butyrate. It is a neutral short-chain fatty acid triglyceride that is likely to overcome the pharmacokinetic drawbacks of natural butyrate as a drug. Tributyrin has potent antiproliferative, proapoptotic and differentiation-inducing effects in neoplastic cells. Compared with butyrate, tributyrin has more favorable pharmacokinetics and is well tolerated. Because it is rapidly absorbed and chemically stable in plasma, tributyrin diffuses through biological membranes and is metabolized by intracellular lipases, releasing therapeutically effective butyrate over time directly into the cell. Tributyrin may, at least in part, exert its growth-reducing and differentiation-inducing effect in Caco-2 cells by an upregulation of the vitamin D receptor; this may provide a useful therapeutic approach in chemoprevention and treatment of colorectal cancer. In phase I study of the orally administered tributyrin there was no consistent increase in hemoglobin F. Peak plasma butyrate concentrations occurred between 0.25 and 3 h after dose. Development of tributyrin as an anticancer agent was discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (MIXED)
Feneritrol is a hypocholesteraemic agent.
Status:
Investigational
Source:
NCT00003667: Phase 2 Interventional Completed Sarcoma
(1998)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
USAN:PHENBUTAZONE SODIUM GLYCERATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
There is no information about biological and/or pharmacological application of phenbutazone sodium glycerate.
Status:
Designated
Source:
FDA ORPHAN DRUG:933223
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
